Gilead Sciences (GILD) Profit After Tax (2009 - 2026)
Gilead Sciences (GILD) reported Profit After Tax of $2.0 billion for Q1 2026, up 53.69% on a YoY basis from $1.3 billion in Q1 2025, and down 7.42% quarter-over-quarter from $2.2 billion in Q4 2025.
Gilead Sciences (GILD) Profit After Tax (2009 - 2026) Analysis & Trends
Gilead Sciences has reported Profit After Tax for 18 years, with the latest figure at $2.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax rose 53.69% year-over-year to $2.0 billion; the trailing twelve-month figure through Mar 2026 stood at $9.2 billion (up 54.5% YoY), and the FY2025 full-year result was $8.5 billion, up 1672.92% from the prior year.
- Profit After Tax for Q1 2026 stood at $2.0 billion, down from $2.2 billion in the prior quarter.
- The five-year high for Profit After Tax was $3.1 billion in Q3 2025, with the low at -$4.2 billion in Q1 2024.
- Historically, Profit After Tax has averaged $1.2 billion across 5 years, with a median of $1.6 billion in 2022.
- Annual changes were most pronounced in 2023 — Profit After Tax jumped 5215.79% — and 2024, when it sank 512.87%.
- Gilead Sciences' Profit After Tax stood at $1.6 billion in 2022, then slipped by 14.68% to $1.4 billion in 2023, then increased by 29.48% to $1.8 billion in 2024, then increased by 22.43% to $2.2 billion in 2025, then slipped by 7.42% to $2.0 billion in 2026.
- The last three Profit After Tax figures came in at $2.0 billion (Q1 2026), $2.2 billion (Q4 2025), and $3.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 2.48 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -4.24 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.02 Bn |
| Dec 31, 2025 | 2.18 Bn |
| Sep 30, 2025 | 3.05 Bn |
| Jun 30, 2025 | 1.96 Bn |
| Mar 31, 2025 | 1.32 Bn |
| Dec 31, 2024 | 1.78 Bn |
| Sep 30, 2024 | 1.25 Bn |
| Jun 30, 2024 | 1.61 Bn |
| Mar 31, 2024 | -4.17 Bn |
| Dec 31, 2023 | 1.38 Bn |
| Sep 30, 2023 | 2.17 Bn |
| Jun 30, 2023 | 1.05 Bn |
| Mar 31, 2023 | 1.01 Bn |
| Dec 31, 2022 | 1.61 Bn |
| Sep 30, 2022 | 1.79 Bn |
| Jun 30, 2022 | 1.14 Bn |
| Mar 31, 2022 | 19.00 Mn |
| Dec 31, 2021 | 358.00 Mn |
| Sep 30, 2021 | 2.59 Bn |
| Jun 30, 2021 | 1.52 Bn |